Picture: B Medical Systems

B Medical Systems’ Ultra-Low Freezers are renowned internationally for their reliability and safety.

Picture: SOM Biotech

The current COVID-19 pandemic situation has shown that repurposing drugs can be crucial for delivering new treatments to patients with agility. Existing drugs can be developed to bring fast, safe and cost-effective treatments for a wide range of conditions. The improved use of data and the development of advanced AI-based technologies enable the fast and effective identification of drugs, accelerating drug discovery, repurposing and innovation.

Picture: Merck KGaA

Development of the large-scale vaccine production process remains an inherently challenging undertaking. Given this complexity, it is more important than ever for vaccine manufacturers to collaborate with experienced technology providers. Such partners can provide critical support from development through manufacturing, helping to eliminate bottlenecks and accelerating production of urgently needed vaccines.

Picture: ScanBalt

The COVID-19 pandemic is putting our health systems in Europe to the test. Capacity bottlenecks are becoming apparent, as are long-neglected investments in modern infrastructure. As the pandemic does not stop at national borders, cross-border healthcare solutions are more urgent than ever.

One of the high-level panels during the virtual Global Bioeconomy Summit 2020 with the Editor-in-Chief of Nature Magazine, Magdalena Skipper (left).

More than 3,000 attendees are participating in the Global Bioeconomy Summit, currently taking place virtually until 20th November. Today, the plenary program and the livestream of the conference kicked-off. 

Fraunhofer ITEM staff present the final vial of the fill and finish campaign of the first larger GMP manufacturing run using an innovative cell pool technology that allowed much faster production. © Prof. Holger Ziehr

As investments into COVID-19 therapeutics is no EU priority, development is lagging behind the US. Now, CORAT Therapeutics‘ candidate COR101 is set to enter clinical testing. 

Thomas Struckmeyer will join the BioChek Group based in Reeuwijk as new CEO from mid-December. He succeeds Barend van Dam, who will assume the position of CEO of the BioChek Group.

© Tumisu/Pixabay.com

After BioNTech SE reported that its COVID-19 vaccine candidate BNT162b2 was over 90% efficient in a Phase III trial, Moderna Inc announced an efficacy of 94.5%.

Picture: ©Evotec

Evotec SE is set to expand the company’s existing campus in Milton Park/Abingdon, UK, into a major, fully-integrated drug discovery and development centre.

©Aymanejed/Pixabay.com

Pfizer and Biontech SE have reached an agreement with the European Commission to supply 200 million doses of their mRNA-based COVID-19 vaccine candidate.